Ann: Appendix 3B, page-10

Can't guess the time to recommence or decision to abort the study or even all studies.
The process would involve ; pathological findings, assessment and principal investigator mediation. That is, if it is that ptx200 was in part or whole the effect then Jeff would need to review options. For example, risk to reward ratio, cohort exclusion, pre entry disclosure ect.
A new plan, of course, needs to be approved by the FDA...
To add, if it was a monotherapy as opposed to the current triangulation, decision making would appear to be more promt.
Hope that helps.